Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL
AbstractThe hypothesis that raising high-density lipoprotein cholesterol (HDL-C) levels could improve the risk for cardiovascular disease (CVD) is facing challenges. There is multitudinous clear clinical evidence that the latest failures of HDL-C-raising drugs show no clear association with risks for CVD. At the genetic level, recent research indicates that steady-state HDL-C concentrations may provide limited information regarding the potential antiatherogenic functions of HDL. It is evident that the newer strategies may replace therapeutic approaches to simply raise plasma HDL-C levels. There is an urgent need to identify an efficient biomarker that accurately predicts the increased risk of atherosclerosis (AS) in patients and that may be used for exploring newer therapeutic targets. Studies from recent decades show that the composition, structure and function of circulating HDL are closely associated with high cardiovascular risk. A vast amount of data demonstrates that the most important mechanism through which HDL antagonizes AS involves the reverse cholesterol transport (RCT) process. Clinical trials of drugs that specifically target HDL have so far proven disappointing, so it is necessary to carry out review on the HDL therapeutics. View Full-Text
Share & Cite This Article
Cao, P.; Pan, H.; Xiao, T.; Zhou, T.; Guo, J.; Su, Z. Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. Int. J. Mol. Sci. 2015, 16, 17245-17272.
Cao P, Pan H, Xiao T, Zhou T, Guo J, Su Z. Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. International Journal of Molecular Sciences. 2015; 16(8):17245-17272.Chicago/Turabian Style
Cao, Peiqiu; Pan, Haitao; Xiao, Tiancun; Zhou, Ting; Guo, Jiao; Su, Zhengquan. 2015. "Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL." Int. J. Mol. Sci. 16, no. 8: 17245-17272.